» Articles » PMID: 25889930

Stratification of Coronary Artery Disease Patients for Revascularization Procedure Based on Estimating Adverse Effects

Overview
Publisher Biomed Central
Date 2015 Apr 19
PMID 25889930
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Percutaneous coronary intervention (PCI) is the most commonly performed treatment for coronary atherosclerosis. It is associated with a higher incidence of repeat revascularization procedures compared to coronary artery bypass grafting surgery. Recent results indicate that PCI is only cost-effective for a subset of patients. Estimating risks of treatment options would be an effort toward personalized treatment strategy for coronary atherosclerosis.

Methods: In this paper, we propose to model clinical knowledge about the treatment of coronary atherosclerosis to identify patient-subgroup-specific classifiers to predict the risk of adverse events of different treatment options. We constructed one model for each patient subgroup to account for subgroup-specific interpretation and availability of features and hierarchically aggregated these models to cover the entire data. In addition, we deviated from the current clinical workflow only for patients with high probability of benefiting from an alternative treatment, as suggested by this model. Consequently, we devised a two-stage test with optimized negative and positive predictive values as the main indicators of performance. Our analysis was based on 2,377 patients that underwent PCI. Performance was compared with a conventional classification model and the existing clinical practice by estimating effectiveness, safety, and costs for different endpoints (6 month angiographic restenosis, 12 and 36 month hazardous events).

Results: Compared to the current clinical practice, the proposed method achieved an estimated reduction in adverse effects by 25.0% (95% CI, 17.8 to 30.2) for hazardous events at 36 months and 31.2% (95% CI, 25.4 to 39.0) for hazardous events at 12 months. Estimated total savings per patient amounted to $693 and $794 at 12 and 36 months, respectively. The proposed subgroup-specific method outperformed conventional population wide regression: The median area under the receiver operating characteristic curve increased from 0.57 to 0.61 for prediction of angiographic restenosis and from 0.76 to 0.85 for prediction of hazardous events.

Conclusions: The results of this study demonstrated the efficacy of deployment of bare-metal stents and coronary artery bypass grafting surgery for subsets of patients. This is one effort towards development of personalized treatment strategies for patients with coronary atherosclerosis that could significantly impact associated treatment costs.

Citing Articles

Economic evaluations of big data analytics for clinical decision-making: a scoping review.

Bakker L, Aarts J, Uyl-de Groot C, Redekop W J Am Med Inform Assoc. 2020; 27(9):1466-1475.

PMID: 32642750 PMC: 7526472. DOI: 10.1093/jamia/ocaa102.

References
1.
Serruys P, Ong A, van Herwerden L, Sousa J, Jatene A, Bonnier J . Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol. 2005; 46(4):575-81. DOI: 10.1016/j.jacc.2004.12.082. View

2.
Mohr F, Morice M, Kappetein A, Feldman T, Stahle E, Colombo A . Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013; 381(9867):629-38. DOI: 10.1016/S0140-6736(13)60141-5. View

3.
Bavry A, Kumbhani D, Helton T, Borek P, Mood G, Bhatt D . Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med. 2006; 119(12):1056-61. DOI: 10.1016/j.amjmed.2006.01.023. View

4.
Serruys P, Onuma Y, Garg S, Vranckx P, De Bruyne B, Morice M . 5-year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. J Am Coll Cardiol. 2010; 55(11):1093-101. DOI: 10.1016/j.jacc.2009.11.049. View

5.
Hong S, Lim D, Seo H, Kim Y, Shim W, Park C . Percutaneous coronary intervention with drug-eluting stent implantation vs. minimally invasive direct coronary artery bypass (MIDCAB) in patients with left anterior descending coronary artery stenosis. Catheter Cardiovasc Interv. 2004; 64(1):75-81. DOI: 10.1002/ccd.20238. View